Conclusion and future prospects

Basit Öğe Kaydı
dc.contributor.authorUludağ Anıl, İnci
dc.contributor.authorÖzcan, Burcu
dc.contributor.authorÖzyurt, Canan
dc.contributor.authorDemirbakan, Burçak
dc.contributor.authorKemal Sezgintürk, Mustafa Kemal
dc.date.accessioned2026-02-03T11:53:49Z
dc.date.available2026-02-03T11:53:49Z
dc.date.issued2025
dc.departmentÇanakkale Onsekiz Mart Üniversitesi
dc.description.abstractLateral flow assays (LFAs) are regarded as a significant technique because of their extensive variety of applications. As discussed in this chapter, they are used in a variety of areas, including clinical diagnostics, environmental surveillance, food safety, hormone balance assessment, cancer biomarker identification, and toxin analysis. Although these tests are renowned for their ability to deliver quick and uncomplicated outcomes, they do have several drawbacks, including limited sensitivity and the need for multiple testing. Advancements in technology have provided substantial breakthroughs to address the constraints of LFAs. Recent advancements in nanoparticles, particularly gold nanoparticles, quantum dots, and magnetic nanoparticles, have greatly enhanced the ability to amplify signals and identify many targets. These nanoparticles enhance the sensitivity of LFAs, facilitating the identification of targets even at low concentrations. Furthermore, LFAs that utilize aptamers have the added benefits of increased stability and reduced costs as compared to systems that rely on antibodies. Aptamers can be readily customized with diverse functional groups, offering versatility in experimental design and optimization. Furthermore, the incorporation of surface-enhanced Raman spectroscopy technology enhances the sensitivity of LFAs, allowing for the detection of substances even at lower concentrations. Consequently, the advancement of technology has enhanced the sensitivity and enhanced the user-friendliness of these tests. © 2026 Elsevier Inc. All rights reserved..
dc.identifier.doi10.1016/B978-0-443-23883-3.00017-9
dc.identifier.endpage490
dc.identifier.isbn9780443238840
dc.identifier.isbn9780443238833
dc.identifier.scopus2-s2.0-105026833715
dc.identifier.scopusqualityN/A
dc.identifier.startpage479
dc.identifier.urihttps://doi.org/10.1016/B978-0-443-23883-3.00017-9
dc.identifier.urihttps://hdl.handle.net/20.500.12428/34312
dc.indekslendigikaynakScopus
dc.language.isoen
dc.publisherElsevier
dc.relation.publicationcategoryKitap Bölümü - Uluslararası
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_Scopus_20260130
dc.subjectClinical diagnostics
dc.subjectEnvironmental surveillance
dc.subjectFood safety
dc.subjectLateral flow assay
dc.subjectPoint-of-care testing
dc.titleConclusion and future prospects
dc.typeBook Chapter

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu